Synthesis and anti-inflammatory properties of 1 α,25-dihydroxy-16- ene-20-cyclopropyl-24-oxo-vitamin d 3, a hypocalcemic, stable metabolite of 1α,25-dihydroxy-16-ene-20-cyclopropylvitamin D 3

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2204-2213

  Laverny, Gilles ^a   Penna, Giuseppe ^a   Uskokovic, Milan ^b   Marczak, Stanislaw ^b   Maehr, Hubert ^b   Jankowski, Pawel ^b   Ceailles, Caroline ^c   Vouros, Paul ^c   Smith, Brenden ^d   Robinson, Matthew ^d   Reddy, G Satyanarayana ^d,e   Adorini, Luciano ^a,f  

^a BioXell SpA   (Italy)

^b Bioxell Inc   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d Epimer LLC   (United States)

^e BROWN UNIVERSITY   (United States)

^f INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA,25 DIHYDROXY 16 ENE 20 CYCLOPROPYL 24 OXOVITAMIN D3; 1ALPHA,25 DIHYDROXY 16 ENE 20 CYCLOPROPYLVITAMIN D3; ANTIINFLAMMATORY AGENT; CALCITRIOL; COLECALCIFEROL DERIVATIVE; DRUG METABOLITE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23P40; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; HYPOCALCEMIA; IMMUNOREGULATION; MOUSE; NONHUMAN; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; CALCITRIOL; CALCIUM; CATHELICIDINS; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; RATS; RECEPTORS, CALCITRIOL; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249116273     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801365a     Document Type: Article

References (40)

1. Adorini, L.; Penna, G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008, 4, 404-412.
2. Evans, R. M. The nuclear receptor superfamily: a rosetta stone for physiology. Mol. Endocrinol. 2005, 19, 1429-1438.
3. Carlberg, C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent. Resultss. Cancer. Res. 2003, 164, 29-42.
4. Fogh, K.; Kragballe, K. New vitamin D analogs in psoriasis. Curr. Drug Targets Inflamm. Allerev 2004, 3, 199-204.
5. Cantorna, M. T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol. 2006, 92, 60-64.
6. Campbell, M. J.; Adorini, L. The vitamin D receptor as a therapeutic target. Expert Opin. Ther. Targets 2006, 10, 735-748.
7. Penna, G.; Amuchastegui, S.; Cossetti, C; Aquilano, F.; Mariani, R.; Sanvito, F.; Doglioni, C; Adorini, L. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol. 2006, 177, 8504-8511.
8. Bouillon, R; Okamura, W.; Norman, A. Structure-function relationships in the vitamin D endocrine system. Endocr. ReV. 1995, 16, 200- 257.
9. Mathieu, C.; Adorini, L. The coming of age of 1, 25-dihydroxyvitamin D (3) analogs as immunomodulatory agents. Trends Mol. M Ed. 2002, 8, 174-179.
10. Nagpal, S.; Na, S.; Rathnachalam, R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 2005, 26, 662-687.
11. Crescioli, C.; Ferruzzi, P.; Caporali, A.; Scaltriti, M.; Bettuzzi, S.; Mancina, R.; Gelmini, S.; Serio, M.; Villari, D.; Vannelli, G. B.; Colli, E.; Adorini, L.; Maggi, M. Inhibition of prostate cell growth by 138, a 1 analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J Endocrino. 2004, 150, 591-603.
12. Adorini, L.; Penna, G.; Amuchastegui, S.; Cossetti, C.; Aquilano, F.; Mariani, R.; Fibbi, B.; Morelli, A.; Uskokovic, M.; Colli, E.; Maggi, M. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist elocalcitol. J. Steroid Biochem. Mol. Biol. 2007, 103, 689-693.
13. Colli, E.; Rigatti, P.; Montorsi, F.; Artibani, W.; Petta, S.; Mondaini, N.; Scarpa, R.; Usai, P.; Olivieri, L.; Maggi, M. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. 2006, 49, 82-86.
14. Uskokovic, M. R.; Manchand, P.; Marczak, S.; Maehr, H.; Jankowski, P.; Adorini, L.; Reddy, G. S. C-20 cyclopropyl vitamin D3 analogs. Curr. Top. Med. Chem. 2006, 6, 1289-1296.
15. Lemire, J. M.; Archer, D. C; Reddy, G. S. 1, 25-Dihydroxy-24-oxo- 16-ene-vitamin D3, a renal metabolite of the vitamin D analog 1, 25- dihydroxy-16-ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 1994, 135, 2818-2821.
16. Siu-Caldera, M. L.; Clark, J. W.; Santos-Moore, A.; Peleg, S.; Liu, Y. Y.; Uskokovic, M. R.; Sharma, S.; Reddy, G. S. 1 R, 25-dihydroxy- 24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1R, 25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. J. Steraiid Biochem. MolRioL. 1996, 59, 405-412.
17. Siu-Caldera, M. L.; Rao, D. S.; Astecker, N.; Weiskopf, A.; Vouros, P.; Konno, K.; Fujishima, T.; Takayama, H.; Peleg, S.; Reddy, G. S. Tissue specific metabolism of 1 α, 25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells
18. (UMR 106 and ROS 17/2.8). J. Cell. Biochem 2001, 82, 599-609.
19. Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Mtschler, A.; Moras, D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. U. S. A 2001, 98, 5491-5496.
20. Clerici, M.; Stocks, N. I.; Zajac, R. A.; Boswell, R. N.; Lucey, D. R.; Via, C. S.; Shearer, G. M. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J. Clin. InVest. 1989, 84, 1892-1899.
21. Kerman, R. H.; Susskind, B.; Katz, S. M.; Van Buren, C. T.; Kahan, B. D. Postrenal transplant MLR hypo-responders have fewer rejections and better graft survival than MLR hyper-responders. Transplant. Proc. 1997, 29, 1410-1411.
22. Matsumoto, S.; Marui, S.; Shiho, O.; Tsukamoto, K.; Yoshimura, N.; Oka, T. A novel immunosuppressant, IR-1116, which has a different biological mechanism from that of cyclosporine A. Eur. J. Immunol. 1993, 23, 2121-2128.
23. Cippitelli, M.; Santoni, A. Vitamin D3: a transcriptional modulator of the interferon- /gene. Eur. J. Immunol. 1998, 28, 3017-3030.
24. Romagnani, S. Lymphokine production by human T cells in disease states. Annu. ReV. Immunol. 1994, 12, 227-257.
25. Lemire, J. M.; Archer, D. C..; Beck, L.; Spiegelberg, H. L. Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr 1995 125, 1704S-1708S.
26. Mattner, F.; Smiroldo, S.; Galbiati, F.; Muller, M.; Di Lucia, P.; Poliani, P. L.; Martino, G.; Panina-Bordignon, P.; Adorini, L. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25- dihydroxyvitamin D
27. (3). Eur. J. Immunol. 2000, 30, 498-508.
28. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. ReV. Immunol. 2004 4, 499-511.
29. Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449, 819-826.
30. Bradley, J. R. TNF-mediated inflammatory disease. J. Pathol. 2008, 214, 149-160.
31. Feldmann, M.; Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature 2005, 435, 612-619.
32. Gately, M. K.; Renzetti, L. M.; Magram, J.; Stern, A. S.; Adorini, L.; Gubler, U.; Presky, D. H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. ReV. Immunol 1998, 16, 495-512.
33. Langrish, C. L.; McKenzie, B. S.; Wilson, N. J.; de Waal Malefyt, R.; Kastelein, R. A.; Cua, D. J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 2004, 202, 96-105.
34. Bettelli, E.; Korn, T.; Oukka, M.; Kuchroo, V. K. Induction and effector functions of T (H) 17 cells. Nature 2008, 453, 1051-1057.
35. Horst, R. L.; Reinhardt, T. A.; Reddy, G. S. Vitamin D metabolism. In Vitamin D: Feldman, D., Glorieux, F. H., Pike, J. W., Eds.; Academic Press, Inc.: New York, 2005; pp 15-35.
36. Omdahl, J. L.; May, B. The 25-Hydroxyvitamin D 24-Hydroxylase. In Vitamin D; Feldman, D., Glorieux, F. H., Pike, J. W., Eds.; Academic Press: New York, 2005; pp 85-104.
37. Wang, T. T.; Nestel, F. P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J. W.; Mader, S.; White, J. H. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Ammung. 2004, 173, 2909- 2912.
38. Liu, P. T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B. H.; Krutzik, S. R.; Ochoa, M. T.; Schauber, J.; Wu, K.; Meinken, C.; Kamen, D. L.; Wagner, M.; Bals, R.; Steinmeyer, A.; Zugel, U.; Gallo, R. L.; Eisenberg, D.; Hewison, M.; Hollis, B. W.; Adams, J. S.; Bloom, B. R.; Modlin, R. L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311, 1770-1773.
39. Schauber, J.; Dorschner, R. A.; Coda, A. B.; Buchau, A. S.; Liu, P. T.; Kiken, D.; Helfrich, Y. R.; Kang, S.; Elalieh, H. Z.; Steinmeyer, A.; Zugel, U.; Bikle, D. D.; Modlin, R. L.; Gallo, R. L. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. InVest. 2007, 117, 803-811.
40. Uskokovic, M. R.; Marczak, S.; Jankowski, P.; Adorini, L. Deuteroalkyl vitamin D3 compounds and their pharmaceutical compositions. WO200738250, 2007.